Company: PRME
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001628280-25-018704
Chunk: 54

Company: Prime Medicine, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 54
---
 of PricewaterhouseCoopers LLP’s examination of the Company’s financial statements both with and without management.

Based on these reviews and discussions with management and PricewaterhouseCoopers LLP, we approved the inclusion of the Company’s audited financial statements in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 for filing with the SEC. We also have selected PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, subject to ratification by the Company’s stockholders.

April 22, 2025

| Members of the audit committee |
| Michael Kelly, Chair           |
| Thomas Cahill, M.D., Ph.D.     |
| Wendy Chung, M.D., Ph.D.       |

<div align='center'>34</div>

### CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS
Other than the compensation arrangements for our NEOs and our directors described elsewhere in this proxy statement under “Executive Compensation” and “Director Compensation,” set forth below is a description of transactions or series of transactions since January 1, 2023, to which we were or will be a party, and in which:

• the amount involved in the transaction exceeds, or will exceed, $120,000 (or, if less, 1% of the average of our total asset amounts at December 31, 2023 and 2024); and

• in which any of our executive officers, directors or holder of five percent or more of any class of our capital stock, including their immediate family members or affiliated entities, had or will have a direct or indirect material interest.

#### Participation in our Follow-on Public Offering
Our 5% stockholders and their affiliates purchased an aggregate of 7,200,000 shares of our common stock in our follow-on public offering in February 2024 at the public offering price. The following table sets forth the number of shares of our common stock purchased by 5% stockholders and their affiliates and the aggregate purchase price paid for such shares.

| Stockholder(1)                                     |     | Shares of common stock |           |     | Total purchase price |            |
|:---------------------------------------------------|:----|:-----------------------|----------:|:----|:---------------------|-----------:|
| GV 2023, L.P. (2)                                  |     |                        | 3,200,000 |     | $                    | 20